Literature DB >> 12874491

Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission.

Floyd R Sallee1, Donald L Gilbert, Alexander A Vinks, Jeffrey J Miceli, Lisa Robarge, Keith Wilner.   

Abstract

OBJECTIVE: Ziprasidone is an atypical antipsychotic with a high ratio of 5-HT(2A) to D(2) receptor antagonism. It is also an agonist at 5-HT(1A), which has been shown in rats to increase dopamine in prefrontal cortex. The objective of this study was to probe the dopamine agonist and antagonist pharmacodynamic properties of ziprasidone in youth.
METHOD: A single-dose, open-label study was conducted in 24 youths, 7 to 16 years of age, with Tourette syndrome or chronic tic disorder. Ziprasidone oral suspension (40 mg/mL) was given to achieve 0.2 to 0.3 mg/kg. Patients were subsequently assessed for serum ziprasidone, serum prolactin, and eye blink rates.
RESULTS: Serum ziprasidone peaked 4 hours postdose. Prolactin (baseline mean 7.2 ng/mL, 95% confidence interval [CI] 5.2-9.2) peaked at 4 hours (mean 27.5 ng/mL, 95% CI 22.6-32.3). Eyeblink rates per 5 minutes (baseline mean 60, 95% CI 42-79) peaked at 6 hours (mean 74, 95% CI 52-96).
CONCLUSIONS: Ziprasidone acutely blocks dopamine transmission, as indicated by increased prolactin levels, and, in a delayed fashion, appears to stimulate dopaminergic transmission, as indicated by the increase in spontaneous eye blinks. The mechanism of dopaminergic stimulation is presumed to be indirect, via 5-HT(1A) agonism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874491     DOI: 10.1097/01.CHI.0000046897.27264.46

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  8 in total

Review 1.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Gilles de la Tourette syndrome.

Authors:  R K Saini; J Debnath; S K Sahoo; R Goger
Journal:  Med J Armed Forces India       Date:  2011-10-22

3.  Focus on ziprasidone: a review of its use in child and adolescent psychiatry.

Authors:  Dean Elbe; Carlo G Carandang
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-11

Review 4.  Prolactin serum concentrations during aripiprazole treatment in youth.

Authors:  Daniel J Safer; Chadi A Calarge; Alan M Safer
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-06       Impact factor: 2.576

5.  European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

Authors:  Veit Roessner; Kerstin J Plessen; Aribert Rothenberger; Andrea G Ludolph; Renata Rizzo; Liselotte Skov; Gerd Strand; Jeremy S Stern; Cristiano Termine; Pieter J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785

Review 6.  Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone.

Authors:  Afshan A Khan; Jeffrey R Strawn; Paul E Croarkin
Journal:  Adolesc Health Med Ther       Date:  2010-10-11

7.  New therapeutic approach to Tourette Syndrome in children based on a randomized placebo-controlled double-blind phase IV study of the effectiveness and safety of magnesium and vitamin B6.

Authors:  Rafael Garcia-Lopez; Emilio Perea-Milla; Cesar Ruiz Garcia; Francisco Rivas-Ruiz; Julio Romero-Gonzalez; Jose L Moreno; Vicente Faus; Guadalupe del Castillo Aguas; Juan C Ramos Diaz
Journal:  Trials       Date:  2009-03-10       Impact factor: 2.279

8.  Complex obsessive compulsive and impulsive symptoms in Tourette's syndrome.

Authors:  Donna Palumbo; Roger Kurlan
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.